This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05417269
Recruitment Status : Recruiting
First Posted : June 14, 2022
Last Update Posted : February 23, 2023
Information provided by (Responsible Party):
Imcyse SA

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : May 23, 2025
Estimated Study Completion Date : December 31, 2025
Carlin BP, Louis TA. Bayesian Methods for Data Analysis, 3rd ed. 2009; Boca Raton, FL: CRC Press.
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency. Guideline on the clinical investigation of medicinal products for the treatment of multiple sclerosis. CHMP/771815/2011 Rev. 2. Effective date 1 October 2015.
Guo X, Carlin BP. Separate and joint modeling of longitudinal and event time data using standard computer packages. The American Statistician; 2004; 58, 16-24.
National Cancer Institute (NCI); U.S. Department of health and human services, National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Published: May 28, 2009 (v4.03: June 14, 2010).
National Multiple Sclerosis Society. Who Gets MS?. Accessed 30 March 2016.